Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

27/06/2017 ​Barcelona Synchrotron Park’s sustainable brownfield restoration program presented at AquaConSoil 2017 21/06/2017 Catalonia confirms itself as pole of attraction for foreign investments 15/06/2017 Construction of the Natura Bissé’s new world headquarters is well on its way 06/06/2017 ​Walk in the Park: the biodiversity routes await you 31/05/2017 UAB second most innovative university in Spain 24/05/2017 PRUAB: 10 years in strengthening relationships between research and business fabric
16 17 18 19 20 21 22 23 24 25 26